A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
for Non-squamous Non-small Cell Lung Cancer
Drug: Rilvegostomig
Sites in Stamford, West Haven +59 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06627647·Phase 3·Recruiting·Listed Oct 2024